GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Total Long-Term Liabilities

PHVS (Pharvaris NV) Total Long-Term Liabilities : $0.59 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Pharvaris NV's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was $0.59 Mil.

Pharvaris NV Total Long-Term Liabilities Historical Data

The historical data trend for Pharvaris NV's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Total Long-Term Liabilities Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial - 0.17 0.26 0.05 0.67

Pharvaris NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.05 0.02 0.67 0.59

Pharvaris NV Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Pharvaris NV Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Total Long-Term Liabilities
Comparable Companies
SNDX CRMD SYRE QURE WVE CVAC GERN ELVN ZYME NTLA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
9EN:Germany
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Website
https://www.pharvaris.com
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.